Cargando…

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China

BACKGROUND: Multiple myeloma is genetically heterogeneous, and chromosome abnormalities play a pivotal role in prognosis. A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities; however, its relationship with overall survival (OS) and progression-free survival (PFS) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qingxiao, Han, Xiaoyan, Zheng, Gaofeng, Yang, Yang, Li, Yi, Zhang, Enfan, Yang, Li, Dong, Mengmeng, He, Donghua, He, Jingsong, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808074/ https://www.ncbi.nlm.nih.gov/pubmed/36605445 http://dx.doi.org/10.3389/fonc.2022.1084683

Ejemplares similares

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2019)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models
por: He, Donghua, et al.
Publicado: (2016)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
por: Tang, Hoi Ki Karen, et al.
Publicado: (2022)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells
por: Lin, Xuanru, et al.
Publicado: (2017)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair
por: Guo, Xing, et al.
Publicado: (2018)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma
por: Xu, Ruyi, et al.
Publicado: (2019)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
por: Hanamura, Ichiro
Publicado: (2021)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

Emerging agents and regimens for multiple myeloma
por: Yang, Yang, et al.
Publicado: (2020)

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways
por: Qu, Jianwei, et al.
Publicado: (2021)

The many substrates and functions of NEDD4-1
por: Huang, Xi, et al.
Publicado: (2019)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis
por: Liu, Yang, et al.
Publicado: (2022)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens
por: Wang, Hua, et al.
Publicado: (2019)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis
por: Yan, Haimeng, et al.
Publicado: (2019)

The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis
por: He, Donghua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gdk8eeecgoom0ois7jaan5np0b